 Home > Biochemistry News > Biotechnology News > Merck's MET inhibitor Tepmetko is approved by the UK MHRA for the treatment of NSCLC patients

Merck's MET inhibitor Tepmetko is approved by the UK MHRA for the treatment of NSCLC patients

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

drug classifications chart

ipratropium drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, the British Medicines and Healthcare Products Regulatory Agency (MHRA) announced the conditional approval of Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer (NSCLC) patients

The MHRA's decision to approve Teppetko was mainly based on the results of the Phase II VISION study, which evaluated Teppetko alone to treat patients with advanced or metastatic NSCLC with skip changes in METex14

Tepmetko is an oral MET kinase inhibitor developed internally by Merck.

In July this year, the British MHRA issued positive scientific opinions on Merck’s targeted anticancer drug Teppetko for the treatment of advanced non-small cell lung cancer (NSCLC) patients with skipping changes in exon 14 of the MET gene

It is worth noting that the authorization of Teppetko was carried out through the ORBIS project, which is a way coordinated by the U.

In March 2020, the drug was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW), making Teppetko the world's first oral MET inhibitor approved for the treatment of advanced NSCLC patients with MET genetic changes

Reference source:

MHRA backs Merck's MET inhibitor Tepmetko

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.